Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 3/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.42 |
| ▸ | CCR5 | P51681 | 1/20 | 0.42 |
| ▸ | CCR8 | P51685 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 3/20 | 0.38 |
| ▸ | LATS1 | O95835 | 10/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | LATS2 | Q9NRM7 | 5/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2711929 | 0.83 | SMN1; SMN2 (0.45) | CYP2A6CCR1CCR5CCR8 | |
| SCHEMBL2124649 | 0.82 | KDM4E (0.49) | PIK3CACYP2A6CCR1CCR5CCR8 | |
| SCHEMBL2124596 | 0.80 | PIK3CA (0.47) | PIK3CACCR1CCR5CCR8 | |
| SCHEMBL2608586 | 0.77 | DHODH (0.42) | PIK3CACYP2A6DHODHLATS1LATS2 | |
| SCHEMBL2126711 | 0.74 | PIK3CA (0.43) | PIK3CADHODHLATS1IDO1 | |
| SCHEMBL2123504 | 0.74 | PIK3CA (0.48) | PIK3CACYP2A6CCR1CCR5CCR8 | |
| SCHEMBL249770 | 0.73 | CCR1 (0.42) | PIK3CACYP2A6CCR1CCR5CCR8 | |
| SCHEMBL2123197 | 0.73 | RORC (0.43) | DHODHLATS1IDO1LATS2 | |
| SCHEMBL2124665 | 0.72 | KDM4C (0.50) | PIK3CADHODH | |
| SCHEMBL2126492 | 0.71 | CCR1 (0.40) | PIK3CACYP2A6CCR1CCR5CCR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| EP-2632422-A1 | ACTIVE INGREDIENT COMBINATION AND ANTI-DANDRUFF HAIR TREATMENT PRODUCTS III | Henkel AG & Co. KGaA (DE) | 2013-09-04 | — | — | EP | disclosed |
| EP-2632417-A1 | ACTIVE INGREDIENT COMBINATION AND ANTI-DANDRUFF HAIR TREATMENT PRODUCTS II | Henkel AG & Co. KGaA (DE) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012055586-A1 | ACTIVE INGREDIENT COMBINATION AND ANTI-DANDRUFF HAIR TREATMENT PRODUCTS II | HENKEL AG & CO. KGAA (DE) | 2012-05-03 | — | — | WO | disclosed |
| WO-2012055587-A1 | ACTIVE INGREDIENT COMBINATION AND ANTI-DANDRUFF HAIR TREATMENT PRODUCTS III | HENKEL AG & CO. KGAA (DE) | 2012-05-03 | — | — | WO | disclosed |
| EP-2445902-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES AS INHIBITORS OF PI3K ACTIVITY | Amgen, Inc (US) | 2012-05-02 | — | — | EP | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2010151737-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
| WO-2010151737-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | PIK3CA 28/4885CYP2A6 2468/4885CCR1 1195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.